Design and synthesis of novel multi-target tetrabromophthalimides as CBS and Topo-II inhibitors and DNA intercalatorsElectronic supplementary information (ESI) available: GI% of tetrabromophthalimide derivatives (2a–2k) utilizing fifteen cancer and two normal cell lines (Table S1); some reported β-tubulin CBS inhibitors, Topo-II poisons (doxorubicin and mitoxantrone), and Topo-II catalytic inhibitors (etoposide) (Fig. S1); FT-IR, 1H and 13C NMR, and mass spectra of all candidates (Fig. S2–S31); biological data (Fig. S32–S41) and materials and methods (SI1–SI6). See DOI: https://doi.org/10.1039/d4md00585f

MLA

Abdel-Motaal, Marwa, et al. “Design and Synthesis of Novel Multi-Target Tetrabromophthalimides as CBS and Topo-II Inhibitors and DNA IntercalatorsElectronic Supplementary Information (ESI) Available: GI% of Tetrabromophthalimide Derivatives (2a–2k) Utilizing Fifteen Cancer and Two Normal Cell Lines (Table S1); Some Reported β-Tubulin CBS Inhibitors, Topo-II Poisons (Doxorubicin and Mitoxantrone), and Topo-II Catalytic Inhibitors (Etoposide) (Fig. S1); FT-IR, 1H and 13C NMR, and Mass Spectra of All Candidates (Fig. S2–S31); Biological Data (Fig. S32–S41) and Materials and Methods (SI1–SI6). See DOI: Https://Doi.Org/10.1039/D4md00585f.” MedChemComm, vol. 15, no. 11, Jan. 2024, pp. 3800–16. EBSCOhost, https://doi.org/10.1039/d4md00585f.

APA

Abdel-Motaal, M., Aldakhili, D. A., Farag, A. B., Elmaaty, A. A., Sharaky, M., Mohamed, N. A., Shaaban, S., Alzahrani, A. Y. A., & Al-Karmalawy, A. A. (2024). Design and synthesis of novel multi-target tetrabromophthalimides as CBS and Topo-II inhibitors and DNA intercalatorsElectronic supplementary information (ESI) available: GI% of tetrabromophthalimide derivatives (2a–2k) utilizing fifteen cancer and two normal cell lines (Table S1); some reported β-tubulin CBS inhibitors, Topo-II poisons (doxorubicin and mitoxantrone), and Topo-II catalytic inhibitors (etoposide) (Fig. S1); FT-IR, 1H and 13C NMR, and mass spectra of all candidates (Fig. S2–S31); biological data (Fig. S32–S41) and materials and methods (SI1–SI6). See DOI: https://doi.org/10.1039/d4md00585f. MedChemComm, 15(11), 3800–3816. https://doi.org/10.1039/d4md00585f

Chicago

Abdel-Motaal, Marwa, Dalal Ali Aldakhili, Ayman B. Farag, Ayman Abo Elmaaty, Marwa Sharaky, Nadia A. Mohamed, Saad Shaaban, Abdullah Yahya Abdullah Alzahrani, and Ahmed A. Al-Karmalawy. 2024. “Design and Synthesis of Novel Multi-Target Tetrabromophthalimides as CBS and Topo-II Inhibitors and DNA IntercalatorsElectronic Supplementary Information (ESI) Available: GI% of Tetrabromophthalimide Derivatives (2a–2k) Utilizing Fifteen Cancer and Two Normal Cell Lines (Table S1); Some Reported β-Tubulin CBS Inhibitors, Topo-II Poisons (Doxorubicin and Mitoxantrone), and Topo-II Catalytic Inhibitors (Etoposide) (Fig. S1); FT-IR, 1H and 13C NMR, and Mass Spectra of All Candidates (Fig. S2–S31); Biological Data (Fig. S32–S41) and Materials and Methods (SI1–SI6). See DOI: Https://Doi.Org/10.1039/D4md00585f.” MedChemComm 15 (11): 3800–3816. doi:10.1039/d4md00585f.